Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Read more: https://www.eurekalert.org/pub_releases/2017-12/sc-idn120717.php